As of 6 Nov 2026, Sunil Healthcare trades at 20.2× trailing earnings, below the industry P/E of 28.7×, and the shares are 14% below their 52-week high. Its ROCE of 7.3% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit fell 7.5% and 16% a year over 3 years. Debt is 0.80× equity. It is a small-cap company with a market cap of ₹72 Cr, ranked 126th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 2.6% over the past year.
- ₹74.90
- ₹74.90
- ₹67.31
- ₹71.91
- 782
Health check
- ReturnsBehind
+2.6% over a year, better than 1 of 7 peers.
- Price tagCheaper
P/E 20.2 vs industry 28.7.
- GrowthShrinking
Sales −7.5%, profit −15.7% a year over 3 years.
- ProfitabilityWeak
ROCE 7.3% vs peer median 17.9%.
- Balance sheetStretched
Debt 0.80× equity, interest covered 1.5×, Piotroski 9 of 9.
- Red flags3 to check
Return on equity is low at 5.9%.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹72 Cr
- Small cap
- P/E
- 20.2
- Industry 28.7
- Price to book
- 1.03
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 5.9%
- Peers 14.7%
- ROCE
- 7.3%
- Peers 17.9%
- Debt to equity
- 0.80
- Debt ₹56 Cr
- EPS (TTM)
- ₹3.47
- Face value ₹10
- OPM (TTM)
- 14.8%
- Net margin 4.2%
- Sales growth
- −16.1%
- Latest quarter vs a year ago
- Profit growth
- −49.0%
- Latest quarter vs a year ago
- Price to sales
- 0.86
- EV/EBITDA 9.9
Strengths and risks
Strengths
- P/E of 20.2 against an industry P/E of 28.7.
Risks to check
- Return on equity is low at 5.9%.
- Quarterly profit down 49.0% on a year ago.
- Quarterly sales down 16.1% on a year ago.
About Sunil Healthcare
Sunil Healthcare Limited engages in the manufacture and sale of empty hard gelatin, hydroxypropyl methylcellulose (HPMC), and pullulan capsules shells in India and internationally. It offers EHG, BSE/TSE free, pearl, liquid fill, preservative free, stick free, flavored, SLS free, natural color, non-AZO, gelatin, HPMC/vegetable, and pullulan capsules. The company also provides ayurvedic products, such as haldi, ginger, vasaka, trifala, guduchi, salaki,…
- Headquarters
- New Delhi
- Employees
- 158
- Sector
- Healthcare
- ISIN
- INE671C01016
- Website
- sunilhealthcare.com
Price range
- Avg volume (3M)
- 512
- 1-year return
- plus 2.6%
- From 52-week high
- minus 14.4%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| SUNLOCSunil Healthcare | 70.19 | minus 2.39% | 72 | 20.2 | 1.03 | 7.3% | 5.9% | 14.8% | −7.5% | −15.7% | 0.00% | plus 2.6% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 22.6 | 23.5 | 21.8 | 19.7 | 19 | |
| 19.4 | 19.6 | 18.2 | 17.8 | 16.1 | |
| 3.3 | 3.9 | 3.6 | 1.9 | 2.9 | |
| 14.5% | 16.7% | 16.6% | 9.9% | 15.4% | |
| 0.9 | 0.4 | 0.5 | 0.4 | 0.2 | |
| 1.4 | 1.4 | 1.7 | 1.7 | 1.5 | |
| 1.7 | 1.6 | 1.6 | 1.5 | 1.5 | |
| – | – | – | −0.1 | – | |
| 1 | 1.3 | 0.8 | −0.9 | 0.2 | |
| 12.0% | 23.5% | 30.5% | 260.0% | −130.6% | |
| 0.9 | 1 | 0.6 | 1.5 | 0.5 | |
| 0.89 | 0.97 | 0.57 | 1.48 | 0.45 |
Profit & loss
- Sales CAGR 3Y
- −7.5%
- Profit CAGR 3Y
- −15.7%
- EPS CAGR 3Y
- −15.7%
- ROE
- 5.9%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 110 | 90.2 | 83.4 | 87.5 | |
| – | minus 18.4% | minus 7.5% | +4.9% | |
| 91.2 | 85.3 | 72.6 | 72.7 | |
| 19.3 | 4.9 | 10.8 | 14.8 | |
| 17.4% | 5.4% | 12.9% | 16.9% | |
| 0.9 | 0.5 | 0.4 | 0.9 | |
| 3.3 | 4.8 | 5.7 | 4.9 | |
| 7 | 6.1 | 6.4 | 6.4 | |
| −0.4 | 2.9 | −0.4 | −2.1 | |
| 9.5 | −2.6 | −1.2 | 2.2 | |
| 29.5% | 30.0% | −16.5% | −79.6% | |
| 6.7 | −1.8 | −1.4 | 4 | |
| 6.52 | -1.74 | -1.38 | 3.91 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 10.3 | 10.3 | 10.3 | 10.3 | |
| 45.7 | 58 | 56.8 | 59.3 | |
| 35.6 | 64.8 | 67.1 | 54 | |
| 29.2 | 25.5 | 27.8 | 40.9 | |
| 121 | 158 | 162 | 165 | |
| 70.4 | 93.2 | 94.3 | 87.6 | |
| 0.1 | 6.1 | 0.2 | 1.8 | |
| – | 2.1 | – | – | |
| 1.6 | 1 | 0 | 0.1 | |
| 48.8 | 56 | 67.4 | 75 | |
| 121 | 158 | 162 | 165 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 7.5 | −15.4 | 11.5 | 22.2 | |
| −3.4 | −10.1 | −7.7 | −2.8 | |
| −3.7 | 25 | −3.9 | −19.3 | |
| 0.3 | −0.5 | −0 | 0 | |
| −4.2 | −10.5 | −9.4 | −3.6 | |
| 3.3 | −25.9 | 2.1 | 18.6 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company.
Major shareholders
Filings & events
News
No recent news coverage found.